P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA

Ítems similars

• The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
  per: Monika Conchon
  Publicat: (2011-12-01)
• Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
  per: Leonardo Caires dos Santos, et al.
  Publicat: (2011-12-01)
• P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
  per: Z. Xu, et al.
  Publicat: (2022-06-01)
• C016 | GENOMIC PROFILING FOR CLINICAL DECISION MAKING IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS.
  per: B. Mora, et al.
  Publicat: (2025-09-01)
• Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
  per: M B Agarwal, et al.
  Publicat: (2015-01-01)